Connect with us

Medically Speaking

Balanced diet: Healthy eating improves quality of life

Dr Suneet Khanna

Published

on

Healthy eating is not about strict dietary limitations, staying unrealistically thin, or depriving yourself of the food you love. A good diet can improve all aspects of life; it is about feeling great, having more energy, improving your mental health, stabilising your mood.

The foods you eat have huge effects on your health and quality of life. If you feel overwhelmed by all the conflicting nutrition and diet advice out there, you’re not alone. It seems that for every expert who tells you a certain food is good for you, you’ll find another saying exactly the opposite. Although eating healthy can be fairly simple, you just have to:

1. Learn how your diet affects your mental as well as your physical health

2. Set yourself up for success by making changes gradually

3. Don’t think of food as “offlimits”

4. Reduce your portion sizes and fill up with more fruit and veg

5. Learn to spot hidden sugar in your food and avoid it

6. Differentiate between healthy and unhealthy fats

7. Find out how fiber intake can fill you and help lose weight

8. Drink plenty of water and keep yourself well-hydrated

We all know that eating right can help you maintain a healthy weight and avoid certain health problems. Various studies have linked eating a typical Western diet filled with processed meats, packaged meals, takeout food, and sugary snacks with higher rates of depression, stress, bipolar disorders, and anxiety.

Eating an unhealthy diet may even result in disorders such as Alzheimer’s disease and schizophrenia or an increased risk of suicide in young people.

 Instead of emphasising on one nutrient, we need to move to food-based recommendations. What we eat should be whole, minimally processed, nutritious food as close to its natural form as possible.

 Here are a few recommendations to have a healthy diet:

1. Have breakfast and eat smaller meals throughout the day

2. Avoid eating late at night

3. Cut back on sugar

4. Moderation and not feeling stuffed is the key to a healthy diet

5. We need a balance of proteins, fat, fiber, carbohydrates, vitamins and minerals to sustain a healthy body.

Dr Suneet Khanna is a well-knwon nutritionist.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Medically Speaking

India to get desi drug for treatment of Covid-19 next week: Chandrasekhar

CSIR-IICT director S. Chandrasekhar tells The Daily Guardian that Ciplenza, indigenous version of Favipiravir, will be much cheaper and thus not out of the reach for common people.

Shalini Bhardwaj

Published

on

To ramp up India’s fight against Covid-19, pharmaceutical company Cipla and CSIR-Indian Institute of Chemical Technology (IICT) have developed Ciplenza (indigenous version of Favipiravir drug) — a convenient and cost-effective drug for Covid treatment. While speaking exclusively to The Daily Guardian, S. Chandrasekhar, director, CSIRIICT, said that the medicine would hit the market next week. He also added that since discovering a drug in such a short time during the pandemic was not possible, they went for “repurposing” an existing drug, which would be cheaper and thus not out of the reach for common people. Excerpts:

S. Chandrasekhar.
S. Chandrasekhar.

Q. When do you think indigenous versions of Favipiravir will be available in the market?

A. The Favipiravir by Glenmark is already in the market. Our collaborator Cipla will make Ciplenza available next week.

Q. What is the concept of repurposing the drug? How is it useful in making Ciplenza?

A. Repurposing means using a drug which was initially discovered for a disease for another disease if symptoms and mode of action are the same. Favipiravir was initially discovered for influenza virus in Japan.

Q. What would be the cost of Ciplenza?

A. Now it is priced at Rs 68 per tablet but it will reduce further depending on the demand and supply.

Q. How much dosage has to be given to the patient?

A. It depends on the patient’s condition but the course is for 14 days: 3.6 gm for the first day and 1.6 gm from the second day.

Q. How did you source the chemicals and reduce the price of the drug?

A. The indigenous chemicals are completely sourced from Indian companies which have helped in bringing down the import dependency so that an affordable version of the drug could be made available for the country.

Q. What was the first thought in your mind about a drug when the pandemic broke out?

A . We had multiple thoughts like discovering a new drug which was not possible quickly; repurpose existing drugs which helped us to work on Favipiravir and Umifenovir and vaccine development which luckily has progressed very well.

Q. What are the challenges you are facing in drug supply during Covid-19 pandemic?

A. There are many challenges including supply chain disruption. Students and faculties had to work at odd conditions because of social distancing. Suddenly the workforce was required to be in isolation to protect them from getting Covid-positive. Also, several students and project staff were stuck at various places but now slowly they are joining.

Continue Reading

Medically Speaking

Son attacks doctor after mother dies of Covid-19

Shalini Bhardwaj

Published

on

A Latur-based doctor was allegedly attacked by the son of a woman who died due to Covid-19. The deceased was admitted to Alfa hospital in Latur in Maharashtra after multiple chronic ailments. Dr Dinesh Verma after checkup informed her kins about her serious condition. Instead of listening to the doctor, the relatives got into a heated argument with him and ultimately the son attacked the doctor with a sharp knife. He stabbed the doctor’s neck, back, chest and hand. The injured doctor was rushed to another hospital. After treatment, his condition is stable now and he has also joined duty. The police have arrested the attacker.

Meanwhile, the Indian Medical Association (Latur and Maharashtra) has registered sharp protests and has also demanded roundthe-clock protection for medical staff. Indian Medical Association headquarters has also strongly condemned the attack on Dr Dinesh Verma and released a statement demanding stringent action against the accused.

Continue Reading

Medically Speaking

Protest at Jhajjar’s medical college continues

Shalini Bhardwaj

Published

on

Even after 10 months, medical students of World College of Medical Sciences in Jhajjar, Haryana, are continuing their protests and are demanding to get themselves transferred to a college recognised by the Medical Council of India (MCI) after court orders. Earlier, their college was refused renewal by the MCI and since the last two years, the students have been struggling to get themselves transferred to an MCI-recognised college.

“We wanted to become doctors but unfortunately, it seems like the nation isn’t worried for us. We have been protesting and have also given applications to the government but nothing has been done. No one is helping us,” protesting students said.They further added,” We qualified NEET examination through the proper channel, paid the fees on time, and passed all exams but we are not getting quality of education and there is no faculty in the college. Our life has been destroyed while studying here.”

“Protesting students of World Medical College Jhajjar have not been shifted to another college even after court orders & MCI’s recommendations. This is beyond imagination and is open hooliganism of college owners. They are trying every possible way from the last 2 years but all in vain because the owner of the college is a very influential and powerful person. The college doesn’t have any facilities for quality medical education so those students should be shifted to other colleges.” said Dr Harjit, AIIMS.

Continue Reading

Medically Speaking

Hepatitis: Debunking common myths and misconceptions

Dr Ansul Gupta

Published

on

Hepatitis is a condition that causes inflammation of the liver. Today, Hepatitis viruses are the most common cause of hepatitis but other infections, toxic substances (e.g. alcohol, certain drugs), and autoimmune diseases can also result in the inflammatory condition of the liver.

There are 5 main types of hepatitis viruses, referred to as A, B, C, D and E. However, the majority of people who have hepatitis are unaware, as it doesn’t often show symptoms right away. If left untreated, hepatitis can lead to serious health problems.

Myths and misconceptions about the disease often stop people from getting diagnosed and prevent early care. Here are of common myths associated with the disease:

Myth 1: All Hepatitis viruses are the same.

Fact: Not all Hepatitis viruses are the same. Hepatitis A, B, C, D, and E are different from diverse methods of transmission and clinical manifestations. While Hepatitis A and E are transmitted through food, Hepatitis B and C are spread through blood transfusion, unprotected sex, and tattoos. Hepatitis D occurs to patients suffering from Hepatitis B.

Myth 2: Don’t eat food prepared by someone with hepatitis. It may be contaminated and you might catch it.

Fact: You may get hepatitis A and E from food prepared by someone with the disease but only if proper hygiene is not maintained. Hepatitis B and C are not transmitted by casual contact.

Myth 3: Women with hepatitis should abstain from breastfeeding their babies to avoid passing the infection.

Fact: Hepatitis C and B are not transmitted through breast milk, although there is a risk of transmission through cracked nipples.

Myth 4: People who have hepatitis B or C should not have children because they will pass it on to them.

Fact: The risk of transmission from mother to baby is different for hepatitis B and hepatitis C. But having either of these conditions is no reason for not having children. Overall, the risk of mother to baby transmission of hepatitis C during birth is very low. It is recommended to consult your doctor. There is a risk of transmitting hepatitis B from mother to infant during the birthing process. However, most transmissions to the baby can be avoided by giving baby hepatitis B immunoglobulin (HBIG) and the first shot of the hepatitis B vaccine at birth.

 Myth 5: People suffering from Hepatitis should consume only bland and boiled food.

Fact: Good nutrition is important during hepatitis. If the patient is nauseated, whatever he/she desires to eat should be welcome. Glucose solution, sugarcane juice, bitter gourd, radish are not recommended. Turmeric has anti-inflammatory properties, it can also be taken.

Myth 6: People with hepatitis can never drink alcohol.

Fact: While it is best to abstain from alcohol if your liver is damaged, people with hepatitis can still drink alcohol in limited quantities, depending on the state of their liver health.

Myth 7: One can differentiate between various types of Acute Viral Hepatitis (AVH) based on clinical symptoms.

Fact: Patients with AVH develop a short febrile illness followed by loss of appetite, highcoloured urine, and vomiting. Jaundice usually lasts for 2 to 3 weeks and may be associated with intense itching. The type of virus can be differentiated only by blood tests.

Myth 8: Vaccine is available against all types of Hepatitis virus.

Fact: Vaccines are available only against Hepatitis A and B.

 Dr Ansul Gupta is Consultant Gastroenterology at Nayati Medicity, Mathura.

Continue Reading

Medically Speaking

Don’t let your guard down, Covid can return: AIIMS Director

Dr Randeep Guleria, Director, All India Institutes of Medical Sciences, Delhi, says there has been no community spread in India yet, but corona cases can spike if precautionary guidelines are not followed.

Shalini Bhardwaj

Published

on

Do you think infection rate has come down in Delhi?

 A. Infection rate is coming down in Delhi and in few other cities as well. It’s possibly increasing in smaller cities as in few cities like in Patna and Guwahati, cases are increasing. So, there are different areas where cases are peaking and flattening at different times. I think certain larger cities have started peaking and flattening but smaller cities are now showing an increase in cases and will peak in a few days.

Q. Serological survey shows infection rate is high in Delhi. What does it mean?

A. It shows there are certain numbers of people who have mild symptoms or are asymptomatic but they had Covid-19 infection. It means that a significant number of people have mild infection as compared to serious infection. We have to continue the protective measures like social distancing, masks, testing, tracking and isolating. If we will not follow such precautionary measures then again people have to face a spike.

Q. Do you think if migrants will return then the cases will rise again? As you said earlier that case would spike again in the month of September?

A. We have to be very careful how to manage when people return back to Delhi or other cities. Monitoring people closely in case of infection and they have to be properly isolated as well. If we are not careful, then there will be a rise in cases.

Q. What is herd immunity? How does it work? Do you think India can get herd-immunity?

A. In case of herd immunity, it has to be 60 percent of positive cases then only it works. We have just 23 percent positive cases, meaning it is going to be difficult to achieve herd immunity; another way to get herd immunity is vaccination. It will help people become immune because this will break the chain and will reduce the number of cases. This virus takes time to make antibodies. In most countries, infection rate is less and for herd immunity infection rate should be high.

Q. Have you seen the mutation of this virus? If there is mutation then it’s going to make the virus more virulent, or does it make it more infectious in increasing cases?

A. A lot of research is going on virus mutation. If it happens then there will always be a mild mutation but till now, we don’t have much data that the virus has changed so much that it’s spreading very rapidly as compared to the past or causing more deaths. Some people have a hypothetical reason that there is less mortality in India or Asia because the virus may have mutated when it came to this part of the world, causing less mortality, but there is now scientific data to support this.

Q. Do you think there is community spread in India?

A. According to the sero survey, there is no community spread. Earlier Bengaluru was doing very well but people started going to the bars, gatherings and the virus again came back. Even now in Delhi cases are coming down significantly. Earlier there were 4,000 cases in a single day but it’s decreased. But on the other hand, the sero survey says that 77 percent of the population is still susceptible therefore you can’t let your guard down and you have to be cautious in terms of social distancing, mask wearing. In Karnataka, they opened up too quickly which led to an increase in the number of cases. It’s also happened in some states of the US.

Q. Do you think Covid-19 can become worse if pollution level is high?

A. There is no conclusive study. I don’t think it’s true. During lockdown pollution came down significantly, but viruses didn’t come down.

 Q. What do you think about school opening for children?

A. It depends on the situation in that particular city. We have to be very careful because if children go to the schools, they won’t be able to maintain social distancing. There may be a certain spread in the school but they might not know that. Children can get the infection and they can take it to their grandparents who can get a very serious infection and that can also lead to a higher chance of death.

Continue Reading

Medically Speaking

India to get Covid vaccine by early 2021, frontline workers will be first priority: Adar Poonawala

The Serum Institute of India CEO, in an exclusive interview, says the company plans to manufacture 300-400 million doses of Covishield by the end of the year, and would like to keep its price under Rs 1,000 initially.

Shalini Bhardwaj

Published

on

Q. What kind of response have you seen in phase 1 and 2 of the clinical trials? When will the Serum Institute conduct trials in India?

A. The phase 1 and 2 trials have been successful in proving the vaccine immunogenic. With that we are now progressing towards the next phase of trials.  We seek to apply for licensure trials in a week’s time in India. With the government fast-tracking everything, we are hoping to get approvals soon. After that we will begin phase 3 (human trials) here in India with 4,000-5,000 people. 

Adar Poonawalla, CEO, Serum Institute of India.

Q. How will this vaccine work? How helpful will it be in stopping the rise of Covid-19 cases?

A. The vaccine, branded as Covishield, is a viral vector type that uses a harmless virus to deliver the genetic material of a pathogen into cells, which is then supposed to create an immune response against the original pathogen. A chimpanzee adenovirus (a common cold virus) has been used by Gilbert and his team to be the carrier. To trick the immune system to fight back Covid-19, the harmless virus was inserted with the SARSCoV-2 virus’ genetic material. 

We can only comment on the efficacy of the vaccine once it clears all the requisite tests and trials. Having said that, so far, the OxfordAstraZeneca vaccine is one of the vaccines which is showing promising results based on ongoing trials and has been cleared for the final phase! 

Q. What should be the target and delivery procedure after getting the vaccine?

A. In the initial phase, it will be a government-administered vaccine programme. It is important to ensure that the vaccine reaches the most vulnerable sections and remotest corners of the country. I feel that the vaccine should be given to vulnerable groups to start with, such as healthcare workers, frontline staff, children and elderly people with weak immune systems. Healthy young adults can get it later. It must be a collective effort amongst all the stakeholders involved.

  Q. What would be the price of the vaccine in India?

 A. It is too early to comment on the pricing, but we would like to keep it under Rs 1,000 initially. However, we are certain that it will be affordable, and hopefully, procured and distributed by governments free of charge in the beginning. 

Q. How many doses have you planned to supply? By when will it reach the masses?

A. Once we get the necessary regulatory approvals, we will start manufacturing large volumes. We will manufacture about 60-70 million doses per month (which might stretch to 100 million doses later). With this, we are looking to manufacture around 300-400 million doses by the end of this year. I believe by the first quarter of the next year it will start reaching the masses. 

Q. How do you plan to manage the manufacturing? Do you have enough capacity to manufacture the Covid-19 vaccine? 

A. Our facility is well-equipped with state-of-the-art technology to manufacture the Covid-19 vaccine. We have dedicated two facilities within our premises to ensure maximum production capacity for the Oxford-AstraZeneca Covid-19 vaccine. We plan to start production post regulatory approvals. 

Q. When are the human trials going to begin in collaboration with Codagenix?

A. The Codagenix candidate is in its pre-trial phase and it is expected to progress to the human trial phase towards the end of this year.

Continue Reading

Trending